Recent Posts

1. 

   It's the first drug shown to slow Alzheimer's. Why is it off to a slow start? | AP News

   The Japs always think they can get by on the cheap and on the quick. There are so many moving parts ro this launch that a top tier, well-resourced company would have a hard time pulling it off. Spoiler alert: Eisai isn’t a top tier company.

   Eisai

   anonymous

   Apr 25, 2024 at 4:53 PM

2. 

   Worst RBM’s at ICT

   Both suck the D hard. Really sad. GR had a chance to replace the disaster that was Mosher with a great leader. He opted for the same old pharma cast off garbage. So here we are.

   Intra-Cellular Therapies

   anonymous

   Apr 25, 2024 at 4:49 PM

3. 

   $44.70 stock close today - thanks Lurch

   Hey Lurch - you were asked a direct question about Sotyktu market share and volume. You completely skirted the answer and the stock reflects investor confidence in you. You done even lie well when you’re on the phone & no one can see you

   Bristol-Myers Squibb

   anonymous

   Apr 25, 2024 at 4:47 PM

4. 

   FiercePharma: Leqembi launch hamstrung by physicians' 'therapeutic nihilism'

   Never. Getting. Approved.

   BiogenIdec

   anonymous

   Apr 25, 2024 at 4:45 PM

5. 

   Investors > employees

   We received the message loud and clear today, investors are more important than us. It was very reassuring hearing our CEO and CFO discuss the productivity and cost savings with investors before us.

   Bristol-Myers Squibb

   anonymous

   Apr 25, 2024 at 4:42 PM

6. 

   Hey AGM’s

   LOL….oncology is the money maker folks!

   Bayer

   anonymous

   Apr 25, 2024 at 4:35 PM

7. 

   Covid Post-Atlanta

   But they are smarter than most people, which means that they're better at whatever they put their minds to - which in turn means the ones who turn to evil, are basically supervillains

   GlaxoSmithKline

   anonymous

   Apr 25, 2024 at 4:32 PM

8. + Show More